Akero Therapeutics, Inc. Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRO

Classifica tra le azioni #3728
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Prezzo delle azioni
$54.65
Ultima sincronizzazione: 2025-12-09
Capitalizzazione di mercato
$4.50B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
1.37%
Paese
US
Scambia Akero Therapeutics, Inc. (AKRO)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Akero Therapeutics, Inc. (AKRO)
L’azione Akero Therapeutics, Inc. (simbolo: AKRO) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Oct 20, 2026.
Una quota di AKRO acquistata prima di Oct 20, 2026 equivale oggi a 0 quote di AKRO.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL